Xiu Laigui

Age: 71 | Residence: Tonghua, China | Citizenship: China | Marital Status: Married | Children: 2

Xiu Laigui’s personal profile reflects the typical trajectory of a Chinese entrepreneur who rose to prominence during the country’s economic reforms. At 71, he is part of a generation that witnessed China’s transformation from a planned economy to a market-driven powerhouse. His residence in Tonghua, rather than a major metropolis like Beijing or Shanghai, suggests a commitment to regional development and possibly a preference for lower-profile living — a trait shared by many Chinese industrialists who maintain strong ties to their hometowns.

His marital status and two children indicate a family structure that may influence succession planning, though no public information is available on whether his children are involved in the business. In many Chinese family-owned enterprises, succession is a critical issue, with younger generations often groomed to take over or brought in as strategic partners. The absence of public succession plans for Xiuzheng Pharmaceuticals may reflect either a deliberate strategy to maintain control or a lack of transparency common in private firms.

His citizenship and residence in China underscore his deep integration into the domestic economic and regulatory environment. Unlike some Chinese billionaires who have sought international assets or residency, Xiu appears to have remained rooted in his home region — a choice that may reflect both personal preference and business strategy, given the importance of local government relationships in China’s pharmaceutical sector.

Age: 71
Source of Wealth: Pharmaceuticals, Self-Made
Residence: Tonghua, China
Citizenship: China
Marital Status: Married
Children: 2

Xiu Laigui’s personal statistics paint a picture of a seasoned entrepreneur who built his fortune through industry-specific expertise and regional market dominance. His self-made status indicates that he did not inherit wealth but instead leveraged his experience — including his early career as a policeman — to identify opportunities in the pharmaceutical sector during a period of rapid economic change in China.

At 71, he is likely approaching or in the later stages of his active business career. Succession planning, corporate governance, and legacy preservation become increasingly important at this stage, particularly for privately held firms where ownership transfer can be complex. The fact that he has two children raises questions about whether they are being prepared to take over the business — a common practice in Chinese family enterprises — or whether he plans to maintain control through trusts, management structures, or eventual sale.

His residence in Tonghua, a city in northeastern China’s Jilin Province, is noteworthy. While many Chinese billionaires relocate to major urban centers for business, lifestyle, or international access, Xiu’s continued presence in Tonghua suggests a strong local network, possibly including government relationships, supply chain infrastructure, and community ties that are integral to Xiuzheng Pharmaceuticals’ operations. This regional anchoring may also reflect a strategic decision to avoid the higher costs and scrutiny associated with major cities.

His citizenship and marital status are standard for Chinese entrepreneurs of his generation, with no indication of dual citizenship or international relocation. This further reinforces his deep integration into China’s domestic economic ecosystem, where success is often tied to navigating local regulations, maintaining government relationships, and serving domestic demand — all areas where Xiu’s background and experience likely provide competitive advantages.

Xiu Laigui’s net worth is derived entirely from his ownership stake in Xiuzheng Pharmaceuticals, a privately held company based in Tonghua, Jilin province, China. As of April 1, 2025, he is ranked #2790 on the Billionaires list and #2980 by global net worth. His wealth is self-made, originating from the pharmaceutical sector, and he is not publicly traded, meaning his net worth is estimated based on private valuations, industry benchmarks, and reported financials from the company or affiliated entities. Unlike publicly listed firms, private pharmaceutical companies like Xiuzheng do not disclose quarterly earnings or balance sheets, making precise valuation challenging. and other wealth trackers typically rely on revenue estimates, profit margins, market share, and comparable public company multiples to derive a reasonable range for private holdings.

His position on the China Rich List peaked at #282 in 2019, suggesting a significant decline in relative ranking over the subsequent years. This could reflect a combination of factors: market consolidation in China’s pharmaceutical sector, regulatory pressures, changes in company valuation methodology, or a shift in the composition of the list itself. It is also possible that the company’s growth trajectory slowed, or that other entrepreneurs in China’s tech and consumer sectors outpaced pharmaceutical wealth accumulation during that period. Without access to Xiuzheng’s internal financials, any assessment of net worth changes must remain speculative and based on external indicators.

As a privately held entity, Xiuzheng Pharmaceuticals’ valuation is not subject to daily market fluctuations like public stocks. Instead, its worth is reassessed periodically by analysts and wealth compilers based on new funding rounds, acquisitions, or industry reports. The company’s geographic concentration in northeastern China may also influence its valuation, as regional economic conditions, infrastructure, and labor costs can affect operational efficiency and scalability. Xiu’s residence in Tonghua, the same city where the company is headquartered, suggests a deep-rooted operational and strategic commitment to the region, which may limit exposure to broader national or global market dynamics but also insulate the business from certain macroeconomic risks.

Given that Xiu Laigui is 71 years old and has two children, succession planning may be a factor influencing the company’s structure and valuation. Family-owned pharmaceutical firms in China often face challenges in transitioning leadership while maintaining operational continuity and investor confidence. If Xiuzheng is structured as a family-controlled enterprise, the net worth attributed to Xiu may include not only his direct equity but also indirect holdings through trusts, family foundations, or affiliated entities. However, such structures are not publicly disclosed in the provided data, and any claims about asset distribution or estate planning would be speculative.

The pharmaceutical industry in China has undergone significant transformation over the past two decades, with increased regulatory oversight, patent reforms, and pressure to innovate beyond generic drugs. Xiuzheng’s ability to adapt to these changes would directly impact its valuation and, by extension, Xiu’s net worth. The company’s size—described as one of China’s largest pharmaceutical firms—implies substantial revenue and market presence, but without specific financial metrics, it is impossible to determine whether this scale translates into profitability or competitive advantage. The absence of detailed financials also means that Xiu’s wealth is not easily comparable to that of publicly listed pharmaceutical billionaires such as Dilip Shanghvi (Sun Pharma) or Sun Piaoyang (Hengrui Medicine), whose net worth is tied to transparent stock prices and audited financial statements.

Xiu Laigui’s wealth trajectory, as captured by rankings, reflects a notable shift in his relative standing among global and Chinese billionaires. In 2019, he ranked #282 on the China Rich List, placing him among the top 300 wealthiest individuals in the country. By 2025, his global ranking had slipped to #2790, indicating either a decline in absolute net worth or, more likely, a rapid expansion of the billionaire class in China and globally, diluting his relative position. This pattern is not uncommon among self-made entrepreneurs in mature industries like pharmaceuticals, where growth rates may lag behind those in tech, e-commerce, or renewable energy sectors that have fueled the rise of newer billionaires.

The absence of year-by-year net worth figures in the provided data makes it impossible to construct a precise wealth history. However, the available rankings suggest that Xiu’s peak visibility in wealth lists occurred around 2019, coinciding with a period of heightened scrutiny and reform in China’s pharmaceutical industry. During this time, the Chinese government implemented policies to reduce drug prices, promote innovation, and consolidate the sector, which may have impacted the valuations of private pharmaceutical firms. Xiuzheng Pharmaceuticals, as a major player, would have been subject to these regulatory shifts, potentially affecting its profitability and, consequently, Xiu’s net worth.

Another factor influencing his wealth history is the private nature of Xiuzheng Pharmaceuticals. Unlike public companies, whose valuations are updated daily based on stock prices, private firms are revalued infrequently and often only when there is a significant event such as a funding round, acquisition, or change in ownership structure. This means that Xiu’s net worth may have remained relatively stable over time, even if his ranking fluctuated due to changes in the broader billionaire landscape. For example, if other billionaires in China’s tech sector experienced rapid wealth growth due to IPOs or stock market surges, Xiu’s static valuation could result in a lower ranking without any actual decline in his assets.

Additionally, the lack of detailed financial disclosures from Xiuzheng Pharmaceuticals means that any assessment of Xiu’s wealth history must rely on indirect indicators. These include industry reports on the pharmaceutical sector’s growth in Jilin province, the company’s market share in key therapeutic areas, and any known expansions or partnerships. Without such data, it is difficult to determine whether Xiu’s wealth has grown, plateaued, or declined over time. The fact that he is still listed as a billionaire in 2025 suggests that Xiuzheng remains a substantial enterprise, but the exact magnitude of his wealth and its evolution remain opaque.

Succession planning and generational wealth transfer may also play a role in his wealth history. At 71 years old, Xiu may be in the process of transitioning control of Xiuzheng Pharmaceuticals to his children or other family members. Such transitions can affect the company’s valuation, especially if there are concerns about leadership continuity or strategic direction. However, the provided data does not include any information about succession plans, board changes, or family involvement in management, making it impossible to assess the impact of these factors on his net worth. In summary, while Xiu Laigui’s wealth history is marked by a peak in 2019 and a subsequent decline in ranking, the underlying causes—whether due to market dynamics, regulatory changes, or company-specific factors—remain speculative without more detailed financial data.

Xiu Laigui operates in the global pharmaceutical industry alongside other self-made billionaires whose wealth stems from domestic market dominance and regulatory navigation. Dilip Shanghvi & family built Sun Pharmaceutical Industries into India’s largest drugmaker, leveraging generics and acquisitions to expand internationally. Pankaj Patel leads Zydus Lifesciences, another major Indian player with a focus on branded generics and innovative drug development. The Setiawan family controls Kalbe Farma in Indonesia, a diversified healthcare group with strong local market penetration. Sun Piaoyang founded Hengrui Medicine in China, a biopharmaceutical firm known for oncology drugs and R&D investment — a contrast to Xiu’s likely focus on established generics and traditional medicine.

These peers share common traits: they are all founders of privately or publicly held pharmaceutical firms in emerging markets, where government policy, pricing controls, and domestic demand shape profitability. Unlike Western pharmaceutical giants that rely heavily on patented blockbusters, these entrepreneurs built empires through volume, distribution efficiency, and regulatory compliance — often in markets with less intellectual property protection but higher population density and unmet medical needs.

Comparing Xiu to these peers reveals both similarities and divergences. While all operate in regulated environments, Xiu’s lack of public disclosure and regional focus in northeastern China make direct financial comparisons difficult. His peers, particularly those with public listings, offer more transparent financial data, allowing for clearer valuation benchmarks. However, Xiu’s private status may afford him greater operational autonomy and less pressure to meet quarterly earnings targets — a strategic advantage in a sector where long-term R&D and regulatory approval cycles are the norm.

Xiu Laigui’s early life is not extensively documented in the provided data, but it is known that he worked as a policeman in China during the early 1990s. This background suggests a formative period in public service, which may have influenced his later approach to business and leadership. The transition from law enforcement to entrepreneurship is not uncommon in China, where many successful business leaders began their careers in state institutions before venturing into private enterprise during the country’s economic reforms. Xiu’s experience as a policeman may have provided him with valuable insights into regulatory environments, organizational discipline, and risk management—skills that would be transferable to running a large pharmaceutical company.

Given that he is now 71 years old, Xiu was likely born in the early 1950s, a period marked by significant political and economic upheaval in China. The Cultural Revolution (1966–1976) and the subsequent economic liberalization under Deng Xiaoping would have shaped his worldview and opportunities. His decision to enter law enforcement in the early 1990s coincides with a period of rapid economic growth and increasing privatization in China, suggesting that he may have been drawn to the stability and structure of public service before recognizing the potential for wealth creation in the private sector.

The lack of detailed information about his education, family background, or early entrepreneurial activities makes it difficult to reconstruct a comprehensive narrative of his early life. However, his eventual success in founding and growing Xiuzheng Pharmaceuticals indicates a strong entrepreneurial drive and an ability to navigate China’s complex regulatory and business environment. His residence in Tonghua, the same city where Xiuzheng is headquartered, suggests that he may have deep local roots and a long-standing commitment to the region, which could have provided him with a network of contacts and resources essential for building a successful pharmaceutical business.

As a self-made billionaire, Xiu’s journey from policeman to pharmaceutical magnate underscores the opportunities available in China’s rapidly evolving economy. His story is emblematic of a generation of entrepreneurs who leveraged their experience in state institutions to build private enterprises, often in sectors that were previously dominated by state-owned enterprises. While the specifics of his early life remain unclear, his career trajectory highlights the importance of adaptability, resilience, and strategic vision in achieving long-term success in China’s competitive business landscape.

Xiu Laigui’s path to wealth is rooted in the pharmaceutical industry, specifically through his ownership and leadership of Xiuzheng Pharmaceuticals, a privately held company based in Tonghua, Jilin province. His transition from a policeman in the early 1990s to a billionaire pharmaceutical entrepreneur illustrates a common trajectory among China’s self-made business leaders: leveraging experience in public service to navigate the complexities of private enterprise. The pharmaceutical sector in China has long been a lucrative industry, driven by a large domestic market, increasing healthcare spending, and government policies aimed at improving access to medicines. Xiu’s ability to build Xiuzheng into one of China’s largest pharmaceutical firms suggests a combination of strategic vision, operational expertise, and an understanding of regulatory dynamics.

The company’s location in northeastern China, a region with a strong industrial base but historically less developed than coastal areas, may have presented both challenges and opportunities. On one hand, operating in a less competitive environment could have allowed Xiuzheng to establish a dominant market position with fewer rivals. On the other hand, the region’s economic constraints, such as limited access to capital and talent, may have required Xiu to be more resourceful and innovative in building the company. His decision to remain headquartered in Tonghua, rather than relocating to a major economic hub, indicates a commitment to regional development and a belief in the long-term potential of the local market.

As a privately owned firm, Xiuzheng Pharmaceuticals’ growth would have been funded through retained earnings, private equity, or bank loans, rather than public stock offerings. This structure allows for greater control and flexibility in decision-making but also limits access to large-scale capital markets. Xiu’s ability to scale the company without going public suggests a disciplined approach to financial management and a focus on sustainable growth. The pharmaceutical industry’s high barriers to entry, including regulatory approvals, R&D costs, and distribution networks, would have required significant investment and patience, qualities that Xiu likely cultivated during his time as a policeman and early entrepreneurial ventures.

The company’s success may also be attributed to its ability to adapt to changing market conditions and regulatory environments. China’s pharmaceutical sector has undergone significant reforms over the past two decades, including efforts to reduce drug prices, promote innovation, and consolidate the industry. Xiuzheng’s ability to navigate these changes and maintain its position as one of China’s largest pharmaceutical firms indicates a strong management team and a resilient business model. Xiu’s leadership would have been critical in guiding the company through these transitions, ensuring that it remained competitive and profitable in a rapidly evolving market.

While the provided data does not include specific details about Xiuzheng’s product portfolio, revenue, or profit margins, the company’s size and Xiu’s billionaire status suggest that it has achieved significant scale and market penetration. The pharmaceutical industry’s reliance on patents, brand recognition, and distribution networks means that Xiuzheng’s success likely stems from a combination of these factors, as well as Xiu’s ability to build and maintain strong relationships with regulators, suppliers, and customers. His journey from policeman to billionaire pharmaceutical magnate is a testament to the opportunities available in China’s dynamic economy and the importance of adaptability, resilience, and strategic vision in achieving long-term success.

Xiu Laigui’s Xiuzheng Pharmaceuticals represents a concentrated, regionally anchored empire in China’s vast but fragmented pharmaceutical sector. Unlike multinational pharma giants, Xiuzheng’s strength lies in its deep penetration of domestic markets, particularly in northeastern China, where its Tonghua base provides logistical and regulatory familiarity. The company’s scale—among China’s largest pharma firms—suggests significant manufacturing capacity and distribution networks, though its private ownership limits transparency on operational metrics. This opacity, while common in China’s private sector, introduces governance risks for external stakeholders. The empire’s durability hinges on its ability to navigate China’s evolving healthcare policies, including price controls and drug reimbursement reforms, which directly impact margins and growth trajectories.

Xiu Laigui’s background as a policeman in the early 1990s suggests a leadership style rooted in discipline, hierarchy, and risk aversion—traits that may have served him well in building a compliant, state-aligned enterprise. His self-made status implies a hands-on, operational approach, likely favoring internal control over delegation. This style may enhance short-term execution but could constrain innovation and agility in a sector increasingly driven by R&D and global standards. The absence of public commentary or corporate governance disclosures further obscures whether leadership is centralized or evolving toward professional management—a critical factor for long-term scalability and investor confidence.

Capital allocation at Xiuzheng appears focused on organic expansion and regional consolidation rather than aggressive M&A or global diversification. With $1.2B net worth and a #2980 global ranking, Xiu’s personal wealth suggests moderate capital deployment relative to peers, possibly reflecting a conservative reinvestment strategy or limited access to external capital due to private ownership. The company’s lack of public financials makes it difficult to assess R&D spend, capex efficiency, or dividend policy. However, its survival and scale in a highly regulated, competitive sector imply disciplined capital stewardship—though this may come at the cost of innovation velocity compared to publicly traded rivals.

Xiuzheng faces multiple layers of risk: regulatory exposure in China’s tightening pharma oversight, reputational vulnerability from opaque operations, and concentration risk tied to its northeastern base. The company’s private status shields it from public scrutiny but amplifies governance concerns, particularly around succession and internal controls. Geopolitical risks include potential U.S.-China tensions affecting supply chains or export markets, though Xiuzheng’s domestic focus may insulate it somewhat. Reputational risk is heightened by the sector’s sensitivity to drug safety and pricing—any scandal could trigger regulatory crackdowns or consumer backlash. The lack of ESG disclosures further limits risk mitigation visibility.

Public records show no significant philanthropic activity tied to Xiu Laigui or Xiuzheng Pharmaceuticals. This absence is not uncommon among China’s private industrialists, particularly those in regulated sectors where public visibility may invite regulatory attention. However, it also represents a missed opportunity to build social capital and mitigate reputational risk. In an era where ESG metrics increasingly influence investor and consumer sentiment, the lack of philanthropy—or even CSR reporting—could become a liability, especially if competitors or state-backed firms position themselves as socially responsible actors.

Xiu Laigui’s influence is likely indirect, channeled through regional economic contributions and compliance with state healthcare priorities rather than overt political engagement. As a private entrepreneur in a strategically vital sector, he operates within China’s “socialist market economy” framework, where alignment with state goals is essential for survival. His residence in Tonghua and company’s regional base suggest localized political ties, possibly through local government partnerships or employment generation. However, without public lobbying records or political appointments, his influence remains transactional rather than institutional—dependent on continued regulatory favor and economic utility to the state.

Xiu Laigui’s legacy is one of pragmatic empire-building in a high-stakes, state-dominated sector. His transition from policeman to pharmaceutical magnate reflects China’s economic transformation and the opportunities available to disciplined, risk-averse entrepreneurs. The durability of his legacy depends on Xiuzheng’s ability to outlive his personal leadership—currently uncertain given the lack of public succession planning. If the company evolves into a professionally managed, innovation-driven entity, his legacy could be that of a foundational builder. If it stagnates or collapses post-succession, he may be remembered as a product of a specific era rather than a transformative figure.

• Profile: Xiu Laigui (
• Billionaires List 2025 (Rank #2980)
• China Rich List 2019 (Rank #282)
• Personal Stats: Age 71, Residence Tonghua, China